Shots:
- The companies collaborated to evaluate BeiGene’s tislelizumab (anti-PD-1 immune checkpoint inhibitor) + PureTech’s LYT-200 (mAb targeting galectin-9) in patients with solid tumors associated with poor survival rates
- LYT-200 is currently being evaluated as a monothx in an adaptive P-I/II clinical trial. PureTech is expected to report the P-I results from LYT-200 monothx in Q4’21 & plans to investigate LYT-200 as a monothx & in combination with other anti-cancer treatments, including CT & other immunotherapies
- PureTech will maintain the LYT-200 program, including global R&D & commercial rights while BeiGene has agreed to supply tislelizumab for use in combination with LYT-200
Click here to read full press release/ article | Ref: Businesswire | Image: PMLive
The post BeiGene Signs a Supply Agreement with PureTech for LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors first appeared on PharmaShots.
